“Stanford researchers reported that levetiracetam slowed diffuse midline glioma growth in mice and was linked to longer survival in patients with diffuse midline gliomas, but not hemispheric high-grade gliomas.”

Checks out so far. 2 hold up so far.

0.9567 under ledger-default@0.3.0 at snapshot 27745 for all claims together. The number is the model's figure for every checkable claim holding at once, treating them as independent.

The statement as a whole, read from the 2 claims below. Each claim is scored on its own; this reading only counts them. Provisional until audited.

Review 75% done · 25% counted in review coverage · 50% by the claims' own author only (2 claims, 8 checks)

Share:

Checked in Galedra: score 0.96, strongly supported · not yet reviewed by anyone else “Stanford researchers reported that levetiracetam slowed diffuse midline glioma growth in mice and was linked to longer survival in patients with diffuse midline gliomas, but not hemispheric…” https://galedra.org/investigations/01a0ea4f-1f17-7826-8abc-1751a0078087

“In mice grafted with human diffuse midline gliomas, levetiracetam slowed malignant-cell growth.”

Supported · 0.9781 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited.

3 of 4 review checks done · 1 counted · 2 by the author only

See the evidence · Claim card

“In medical-record data, levetiracetam use was linked to longer survival for patients with diffuse midline gliomas but not for patients with hemispheric high-grade gliomas.”

Supported · 0.9781 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited.

3 of 4 review checks done · 1 counted · 2 by the author only

See the evidence · Claim card